RxDoctor Payments Data

Doreen Perkins

Nurse Practitioner · Birmingham, ALNPI 1720012305

Payments from drug & device makers

$413in general payments, 2019–2025

Across 14 payments — averaging $29.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$117
  • Sumitomo Pharma America, Inc.$114
  • Calyxo, Inc.$81
  • Astellas Pharma US Inc$21
  • Urovant Sciences Inc$19
  • Advanced Oxygen Therapy Inc.$18
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$413100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Procept Biorobotics Corporation1$117
Sumitomo Pharma America, Inc.6$114
Calyxo, Inc.1$81
Astellas Pharma US Inc1$21
Urovant Sciences Inc1$19
Advanced Oxygen Therapy Inc.1$18
Photocure Inc1$16
Hollister Incorporated1$13
ABC Home Medical Supply, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$413 in reported general payments places this provider in the 60th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$47,624
Medicare patients
380
Services billed
970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron183$134,681
GemtesaVibegron24$17,411
Trospium Chloride ErTrospium Chloride56$13,823
Tolterodine Tartrate ErTolterodine Tartrate50$11,805
Tamsulosin Hcl430$8,654
Trospium Chloride54$5,324
Estradiol62$4,447
Methenamine Hippurate71$4,280
Silodosin18$3,623
Fesoterodine Fumarate ErFesoterodine Fumarate14$3,100
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst96$2,934
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl15$2,891
Finasteride151$2,535
Potassium Citrate ErPotassium Citrate38$2,512
Oxybutynin Chloride ErOxybutynin Chloride83$2,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$21$134,681183 claims
Sumitomo Pharma America, Inc.Gemtesa$114$17,41124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →